Brachyury-directed Vaccine for the Prevention or Treatment of Cancers

Tumor invasion and metastasis are the primary drivers of cancer-related mortality. Therapies that have an ability to specifically target invasive and/or metastatic cells are anticipated to have a significant impact in the clinical management of advanced cancers.

Researchers at the NCI have developed a vaccine technology that stimulates the immune system to selectively destroy metastasizing cells. Brachyury, a master transcription factor that governs the epithelial-mesenchymal transition, was shown to be significantly overexpressed in primary and metastasizing tumors relative to normal human tissues. Stimulation of T cells with the Brachyury peptide promoted a robust immune response and the targeted lysis of invasive tumor cells. Brachyury overexpression has been demonstrated in a range of human tumors (breast, lung, colon and prostate, among others) suggesting that a therapeutic vaccine derived from this technology would be broadly applicable for the treatment of cancer.

Potential Commercial Applications: Competitive Advantages:
  • Preventative cancer vaccine for patients with precancerous lesions of the breast, colon or prostate.
  • Therapeutic cancer vaccine for the treatment of disseminated and late-stage tumors.
  • Vaccine component of a multi-modal cancer therapy
  • Treatment targets invasive and metastatic tumor cells which are the primary cause of cancer-related mortality.
  • Vaccine can eliminate cancer stem cells which are resistant to conventional therapies
  • Compatible with the clinically-proven TRICOM cancer vaccine platform
  • Available (Optimized) for use with non-pox, non-yeast vectors including: adenovirus, lentivirus, etc., and for use with protein- or peptide-based vaccines

Development Stage:
Pre-clinical (in vivo)


Jeffrey Schlom (NCI)  ➽ more inventions...

Claudia Palena (NCI)  ➽ more inventions...

Intellectual Property:
US Application No. 61/701,525
US Application No. 14/428,308
European Application No. 13773456.2

R.I. Fernando et al. PMID: 20071775
C. Palena et al. PMID: 17438107

Collaboration Opportunity:

Licensing and research collaboration

Licensing Contact:
John Hewes, Ph.D.
Phone: 240-276-5515

OTT Reference No: E-055-2011
Updated: Mar 20, 2018